Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant

Table 3 Summary of outcomes in Different Early Conversion Clinical Trials

Ref.	Renal function (Gp1 vs Gp 2)	BPAR (Gp1 vs Gp 2)	Adverse event (Gp1 vs Gp 2)	Remarks
Everolimus
Budde et al[23], 2011, (ZEUS Study)	12 mo Sr. Cr: 141.7 ± 44 μmol/L vs 137.0 ± 43 μmol/L (P = NS) eGFR: 71.8 ± 18 mL/min vs 61.2 ± 16 mL/min (P = 0.000)	9.7% vs 3.4% (P = 0.03)	SAE/Infection: 61% vs 59% (P = NS) UTI: 57.0% vs 53% (P = NS) Diarrhoea: 36% vs 27% (P = NS) HPL: 14% vs 10% (P = NS)	Graft survival: 100% vs 100% (P = NS) Patient survival 100% vs 99% (P = NS)
Mjornstedt et al[24], 2012 (CENTRAL trial)	12 mo Sr. Cr: 122.0 ± 35 μmol/L vs 132.0 ± 45 μmol/L (P = NS) eGFR: 68.1 ± 21.5 mL/min vs 69.4 ± 22.9 mL/min (P = NS)	27.5% vs 11.0% (P = 0.004)	SAE/Infection: 53.9% vs 38.0% (P = 0.025) CMV infection: 8.8% vs 13.0% (P = NS) Edema: 29.4% vs 21.0% (P = NS) Anaemia: 16.7% vs 6.0% (P = 0.02) HPL: 12.7% vs 9.0% (P = NS) Proteinuria: 4.9% vs 0% (P = 0.06) Acne: 12.7% vs 2.0% (P = 0.006) Mouth Ulceration: 12.7% vs 2.0 % (P = 0.001)	Graft survival: 100% vs 100% (P = NS) Patient survival 98% vs 98% (P = NS)
Sirolimus
Lebranchu et al[25], 2009 (CONCEPT Study)	12 mo: Sr. Cr: 117.4 μmol/L vs 132.3 μmol/L (P < 0.001) eGFR: 68.9 mL/min vs 64.4 mL/min (P = 0.017)	16.8% vs 8.2% (P = NS)	Peripheral Edema: 28.1% vs 22.6% (P = NS) SAE/infection: 60% vs 44% (P = 0.025) Diarrhoea: 30.2% vs 9.2% (P < 0.001) Dyslipidemia: 5.20% vs 4.12% (P = NS) Proteinuria: 9.3% vs 3.09 % (P = NS) NODAT: 3.1% vs 2.06% (P = NS) Apthous Stomatitis: 45.8% vs 5.15% (P < 0.001)	Graft Survival: 99% (P = NS) Patient Survival 97% (P = NS)
Guba et al[26], 2010, (SMART Trial)	12 mo: Sr Cr: 111.5 ± 45 mg/dL vs 142.6 ± 74 mg/dL (P = 0.004) eGFR: 64.5 ± 25.2 mL/min vs 53.4 ± 18.0 mL/min (P = 0.001)	17.4% vs 15.5% (P = NS)	Wound Healing Disorder: 10.1% vs 11.3%, (P = NS) Infection: 52.2% vs 60.6% (P = NS) CMV: 7.3% vs 28.2% (P < 0.001) HPL: 20.3% vs 7.0% (P = 0.02) Diarrhoea: 13.0% vs 9.9% (P = NS) Lymphocele: 27.5% vs 23.9% (P = NS)	Graft Survival: 99% vs 97% (P = NS) Patient Survival 99% vs 99% (P = NS)
Weir et al[27], 2010 (Spare the Nephron Trial)	12 mo Sr. Cr: 126.2 ± 82.8 μmol/L vs 145.0 ± 96.5 μmol/L (P = NS) eGFR: 74.6 ± 17.9 mL/min vs 71.5 ± 21.2 mL/min (P = 0.06)	7.4% vs 6.0% (P = NS)	Infection: 16.2% vs 18.3% (P = NS) HPL: 24.3% vs 10.5% (P = 0.000) CMV: 4.7% vs 9.2% (P = NS) Polyoma virus: 2% vs 4% (P = NS) Diarrhoea: 29.7% vs 9.8% (P = 0.001) Malignancy: 4.7% vs 6.5% (P = NS)	Graft Survival: 98% vs 97.4% (P = NS) Patient Survival 100% vs 98% (P = NS)
Heilman et al[28], 2011	12 mo Sr. Cr: 96.1 ± 28 μmol/L vs 106.1 ± 61 μmol/L (P = NS) eGFR: 63.0 ± 19.1 mL/min vs 59.8 ± 18.9 mL/min (P = NS)	13% vs 5% (P = NS)	CMV: 13% vs 13% (P = NS) Polyoma virus: 2% vs 4% (P = NS)	NA

eGFR: Estimated renal function; NA: Not Available; Not Significant; NODAT: New-onset diabetes after transplantation; CMV: Acute cytomegalovirus.